Beta Drugs Share Price | Beta Drugs Stock Screener
BETA
Pharmaceuticals
Share Price NSE
₹2277.20
▼
-37.50 (-1.62%)
As of July 23, 2026, the Beta Drugs share price (NSE: BETA) is ₹2,277.20, down 1.62% from the previous close, with shares trading between ₹2,250.00 and ₹2,399.00, and a 52-week range of ₹1,030.30–₹2,478.40.
Analyse BETA share price charts and track historical price performance.
Use the Beta Drugs stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Beta Drugs Market Cap
₹2,346.39 Cr.
BETA P/E Ratio (TTM)
55.82
Beta Drugs P/B Ratio
10.54
EPS (TTM)
₹40.92
Dividend Yield
-
Debt to Equity
0.43
BETA 52 Week High
₹2478.40
Beta Drugs 52 Week Low
₹1030.30
Operating Margin
19.00%
Profit Margin
9.28%
BETA Revenue (TTM)
₹97.00
EBITDA
₹21.00
Net Income
₹9.00
Total Assets
₹496.00
Total Equity
₹245.00
Beta Drugs Share Price Chart
Screen Beta Drugs share price with an interactive chart. Analyse BETA price trends and volatility across different timeframes.
Beta Drugs Company Profile - Fundamental Screener
Screen Beta Drugs company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for BETA shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE351Y01019
Beta Drugs Balance Sheet Screener
Screen BETA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Total Assets | 496 | 436 | 254 | 198 | 158 | 118 | 107 | 83 | 50 |
| Current Assets | 335 | 331 | 178 | 128 | 97 | 68 | 56 | 43 | 32 |
| Fixed Assets | 125 | 89 | 65 | 63 | 55 | 40 | 44 | 18 | 13 |
| Liabilities | |||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 143 | 136 | 12 | 13 | 17 | 16 | 13 | 9 | 3 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | |||||||||
| Total Equity | 245 | 197 | 157 | 123 | 92 | 69 | 57 | 41 | 33 |
| Share Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 9 | 9 |
| Reserves & Surplus | 235 | 187 | 148 | 113 | 83 | 59 | 48 | 32 | 24 |
Beta Drugs Income Statement Screener - Profit & Revenue Analysis
Screen Beta Drugs income statement and profit fundamentals.
Analyze BETA quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Beta Drugs share price evaluation.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Dec |
|---|---|---|---|---|---|---|---|
| Revenue | 97 | 127 | 98 | 103 | 106 | 90 | 89 |
| Expenses | 76 | 98 | 79 | 81 | 82 | 70 | 72 |
| EBITDA | 21 | 29 | 19 | 23 | 24 | 19 | 17 |
| Operating Profit % | 19.00% | 22.00% | 16.00% | 20.00% | 21.00% | 19.00% | 18.00% |
| Depreciation | 5 | 4 | 4 | 4 | 4 | 4 | 3 |
| Interest | 4 | 3 | 3 | 3 | 4 | 4 | 2 |
| Profit Before Tax | 12 | 22 | 12 | 16 | 16 | 11 | 12 |
| Tax | 3 | 6 | 3 | 4 | 4 | 2 | 3 |
| Net Profit | 9 | 17 | 9 | 12 | 12 | 9 | 9 |
| EPS | 8.93 | 14.78 | 9.40 | 11.59 | 12.10 | 8.40 | 9.31 |
Beta Drugs Cash Flow Screener - Liquidity Fundamentals
Screen BETA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | 36 | 31 | 23 | 30 | 19 | 8 | 0 | 17 |
| Investing Activities | -36 | -14 | -19 | -22 | -6 | -15 | -21 | -11 |
| Financing Activities | 118 | -8 | -3 | -1 | -8 | 9 | 12 | 5 |
| Net Cash Flow | 118 | 10 | 2 | 7 | 5 | 2 | -9 | 12 |
Beta Drugs Shareholding Pattern Screener
See Beta Drugs shareholding pattern with promoter, FII, and DII holdings.
Check Beta Drugs promoter holding and ownership changes for BETA on TickJournal.
| Item | 2026-Mar | 2026-May | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Nov | 2025-Dec | 2024-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 66.73% | 59.10% | 66.73% | 66.73% | 66.73% | 66.73% | 64.90% | 66.73% |
| FII Holding | 0.90% | 2.95% | 0.00% | 0.00% | 0.00% | 0.00% | 1.14% | 0.00% |
| DII Holding | 0.29% | 6.01% | 0.00% | 0.00% | 0.00% | 0.00% | 1.89% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 21.81% | 22.72% | 21.81% | 21.75% | 21.81% | 21.78% | 21.78% | 22.35% |
| Other Holding | 10.26% | 9.22% | 11.45% | 11.51% | 11.45% | 11.49% | 10.29% | 10.91% |
| Shareholder Count | 3,184 | 5,027 | 3,045 | 3,139 | 3,184 | 3,003 | 3,694 | 2,116 |
Beta Drugs Share Dividend Screener - Share Yield Analysis
Check Beta Drugs dividend history with payout and yield data.
View Beta Drugs dividend details including ex-dates and amounts for BETA stock.
Beta Drugs Stock Index Membership
See which indices include Beta Drugs stock.
Check BETA index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Beta Drugs Market Events Screener - Corporate Actions
Get Beta Drugs corporate actions including splits, bonuses, and buybacks.
Check Beta Drugs stock events that may affect BETA share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-07-20 | 2026-07-20 | Quarterly Result Announcement | NA | -3.51% |
| 2026-05-14 | 2026-05-14 | Quarterly Result Announcement | NA | 7.15% |
| 2026-02-14 | 2026-02-14 | Quarterly Result Announcement | NA | -2.75% |
| 2026-02-04 | 2026-02-04 | Extraordinary General Meeting | NA | -9.19% |
| 2025-11-06 | 2025-11-06 | Quarterly Result Announcement | NA | -6.03% |
| 2025-05-15 | 2025-05-15 | Quarterly Result Announcement | NA | 5.92% |
| 2025-03-26 | 2025-03-26 | Bonus | 1:20 | 4.59% |
| 2024-12-21 | 2024-12-21 | Extraordinary General Meeting | NA | -6.02% |
| 2024-11-12 | 2024-11-12 | Extraordinary General Meeting | NA | 15.13% |
| 2024-11-06 | 2024-11-06 | Quarterly Result Announcement | NA | -1.38% |
| 2024-09-30 | 2024-09-30 | Annual General Meeting | NA | -1.01% |
Beta Drugs Competitors Screener - Peer Comparison
Screen BETA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 466,191 | 40.90 | 61,674 | 12.69% | 11,565 | 61.52 |
| Divis Laboratories | 196,088 | 75.78 | 11,067 | 13.95% | 2,568 | 73.60 |
| Torrent Pharmaceuticals | 191,454 | 79.75 | 13,886 | 20.34% | 2,138 | 66.10 |
| Cipla | 114,318 | 29.97 | 29,045 | 2.24% | 3,870 | 47.02 |
| Zydus Life Science | 113,332 | 22.27 | 27,658 | 17.64% | 5,026 | 51.92 |
| Lupin | 110,051 | 21.47 | 29,039 | 26.75% | 5,356 | 47.81 |
| Mankind Pharma | 105,095 | 54.93 | 14,636 | 14.85% | 1,938 | 55.85 |
| Dr Reddys Laboratories | 98,725 | 24.22 | 35,059 | 3.90% | 4,158 | 29.50 |
| Aurobindo Pharma | 88,240 | 26.21 | 33,385 | 3.21% | 3,376 | 49.50 |
| Laurus Labs | 85,179 | 96.66 | 6,868 | 22.01% | 890 | 64.23 |
Beta Drugs Company Announcements - News Screener
Screen BETA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-07-21 | Outcome of Board Meeting | - |
| 2026-07-21 | Statement of deviation(s) or variation(s) under Reg. 32 | - |
| 2026-07-07 | Certificate under SEBI (Depositories and Participants) Regulations, 2018 | - |
| 2026-06-30 | Trading Window | - |
| 2026-06-15 | Spurt in Volume | - |
| 2026-06-12 | Spurt in Volume | - |
| 2026-05-25 | General Updates | - |
| 2026-05-25 | Outcome of Board Meeting | - |
| 2026-05-22 | Analysts/Institutional Investor Meet/Con. Call Updates | - |
| 2026-05-16 | Copy of Newspaper Publication | - |
| 2026-05-15 | Analysts/Institutional Investor Meet/Con. Call Updates | - |
| 2026-05-15 | Analysts/Institutional Investor Meet/Con. Call Updates | - |
| 2026-05-14 | Outcome of Board Meeting | - |
| 2026-05-14 | Statement of deviation(s) or variation(s) under Reg. 32 | - |
| 2026-05-14 | Monitoring Agency Report | - |
| 2026-05-12 | Analysts/Institutional Investor Meet/Con. Call Updates | - |
| 2026-04-25 | Outcome of Board Meeting | - |
| 2026-04-22 | General Updates | - |
| 2026-04-07 | Price movement | - |
| 2026-04-07 | Disclosure under SEBI Takeover Regulations | - |